🧬 BioMed Pulse · 2026-10-31 02:01 UTC
BIOMED PULSE
Saturday, 31 October 2026 | Your daily briefing on longevity, viruses, and new cures
⚡ TL;DR
The Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo has now spread to Kenya and Nigeria, making it the largest Ebola outbreak ever recorded in the DRC; geographic spread across the African Region is accelerating. Mood: high alert on the Ebola front, with multiple concurrent outbreak signals keeping global disease watchers on edge. [1] [2] [3]
🦠 OUTBREAKS & VIRUSES
BUNDIBUGYO VIRUS (EBOLA) - DRC, KENYA, NIGERIA
- As of the 23 October 2026 WHO Disease Outbreak News (DON622), the BVD outbreak has spread beyond the DRC to imported cases confirmed in both Kenya and Nigeria. [3]
- The DRC outbreak was first declared on 15 May 2026 and has since grown to become the largest Ebola outbreak ever reported in that country, expanding faster than any previous Ebola outbreak. [2]
- As of 1 July 2026 (DON612), 1,460 confirmed cases and 452 deaths had been reported from the DRC alone; by 15 July (DON613) those figures had risen to 2,124 confirmed cases and 828 deaths. [1] [4]
- The outbreak initially centered on Mongbwalu health zone in Ituri Province before spreading across six provinces: Bas-Uele, Haut-Uele, Ituri, North Kivu, South Kivu, and Tshopo, and reaching at least 61 health zones. [5] [6]
- A laboratory-confirmed imported case was reported in Kenya on 5 October 2026 in a patient with recent travel history from DRC through Uganda. [7]
- The pathogen is Bundibugyo virus, a distinct Ebola species (species Orthoebolavirus bundibugyoense); cross-border transmission into Uganda was documented as early as May 2026. [8] [9]
- CDC had mobilized international response as of 17 May 2026, deploying personnel and activating airport screening at Washington-Dulles and Atlanta for travelers arriving from affected regions. [10]
LISTERIA - PREPARED MEALS (USA)
- CDC continues to warn consumers as of 30 October 2026 that illnesses are ongoing despite product recalls linked to prepared meals; people are urged to check refrigerators and freezers and discard any recalled items immediately.
SALMONELLA - MORINGA LEAF SUPPLEMENTS (USA)
- A new CDC alert posted 31 October 2026 reports 11 people from 7 states sick with the same Salmonella strain linked to moringa leaf powder supplements.
- This is the latest in a string of moringa-related Salmonella outbreaks; by January 2026, 65 people across 28 states had been affected in an earlier related cluster, and an extensively drug-resistant strain was identified in capsule-form moringa products as of February 2026.
MERS-CoV - SAUDI ARABIA
- Between 1 January and 5 October 2026, Saudi Arabia reported 8 laboratory-confirmed MERS-CoV cases including one death, detected across six locations including Riyadh, Tabuk, Al Jouf, Arar, Hafr Al-Batin, and one additional site.
- MERS-CoV (Middle East Respiratory Syndrome Coronavirus) is a betacoronavirus with dromedary camels as its primary zoonotic reservoir; human-to-human transmission remains limited but sporadic cases continue.
PNEUMONIA OF UNDETERMINED ETIOLOGY - RUSSIA
- On 2 October 2026, WHO became aware of the death of an employee of the Irkutsk Antiplague Research Institute (APRI) of Siberia and the Far East following severe pneumonia; the etiology remains undetermined and WHO is monitoring the situation.
- The Irkutsk APRI works with dangerous pathogens; WHO posted DON620 on 10 October 2026 flagging this event, and the cause of death has not been publicly confirmed as work-related.
DRUG-RESISTANT BACTERIA - USA
- A September 2026 CDC report documented a dramatic increase in dangerous drug-resistant bacteria nationally, underscoring the growing antimicrobial resistance threat in healthcare settings.
- Separately, a July 2026 CDC report showed a decline in healthcare-associated infections overall in 2023, suggesting progress in hospital infection control even as AMR rises externally.
ANIMAL RABIES - USA
- CDC issued a statement in September 2026 on increases in animal rabies activity and associated human exposures, urging vigilance around animal contacts nationwide.
WEST NILE VIRUS - USA
- CDC reported an early and record West Nile virus season as of July 2026, with weekly emergency room visits for mosquito-related illness higher than usual, prompting mosquito-bite prevention messaging.
🧬 LONGEVITY & AGING
NEURONAL SENESCENCE AND SPINAL CORD INJURY
- A study in Genes and Disease (Europe PMC, July 2026) found that the transcription factor Glis1 regulates metabolic programming in neurons by promoting H3K18 lactylation, a histone modification fueled by lactate, helping alleviate neuronal senescence following spinal cord injury.
- H3K18 lactylation is a relatively newly characterized epigenetic mark where lactate directly modifies histones; this study links it mechanistically to slowing the cellular aging process in injured spinal cord tissue.
FERRO-AGING AND INTERVERTEBRAL DISC DEGENERATION
- Research published in Bioactive Materials (Europe PMC, October 2026) describes a strategy called "ferro-aging reprogramming" targeting NOX4 (an enzyme driving oxidative stress and iron-related damage) in aging disc cells, using an iron-chelating therapy that selectively targets senescent cells to treat intervertebral disc degeneration.
- The approach combines senolytics (clearing senescent cells) with iron chelation, addressing a mechanism whereby iron accumulation in aging cells drives ferroptosis-like damage; results showed functional improvement in disc tissue in preclinical models.
mTORC1 SILENCING FOR DISC DEGENERATION
- A separate Bioactive Materials paper (October 2026) from Hiranaka et al. used cationized gelatin nanospheres to deliver RNA interference targeting mTORC1 (a master regulator of cellular metabolism and aging) into disc cells, achieving controlled release and protecting against intervertebral disc degeneration in preclinical work.
- mTORC1 hyperactivation is a known driver of cellular senescence and disc cell death; nanosphere-mediated gene silencing represents a localized anti-aging delivery strategy for musculoskeletal tissue.
CARTILAGE REPAIR AND OSTEOARTHRITIS MICROENVIRONMENT
- A DNA-adsorbing nanozyme hydrogel system published in Bioactive Materials (October 2026) by Yu et al. was shown to reprogram the inflammatory and oxidative microenvironment in osteoarthritic joints to support stem cell-based cartilage regeneration, addressing a core barrier to repair in aging joints.
AI FACE PHOTOGRAPH AGING MODELS
- A model development and validation study published in Lancet Digital Health (Europe PMC) by Haugg, Lee, He, Gladyshev, Aerts, Mak et al. introduced FAHR-Face, a foundation AI model that estimates biological age and health recognition from face photographs alone, validated against clinical outcomes; Gladyshev VN (a leading longevity researcher at Harvard) is among the co-authors.
CARDIAC REPAIR VIA LYMPHANGIOGENESIS
- Liu et al. (Bioactive Materials, October 2026) demonstrated that tissue engineering polymeric formulations can enable lymphangiogenesis, the formation of new lymphatic vessels, to support myocardial repair after injury, an aging-relevant target given the rising burden of heart failure in older adults.
OLDER ADULTS IN HUMANITARIAN CRISES - LANCET SERIES
- A multi-paper series in Lancet Healthy Longev (Europe PMC) highlights that older adults are systematically overlooked and underserved in humanitarian emergencies, lacking access to palliative care, sexual and reproductive health services, and nutrition support.
- The PARTICIPATE framework published in the same series provides a rights-based structure for including older people's healthcare needs in humanitarian crisis planning.
- Authors including de la Fuente-Nunez V (WHO) and collaborators call for person-centered approaches that recognize heterogeneity within older adult populations in conflict and disaster settings.
💊 NEW CURES & APPROVALS
JUBBONTI (DENOSUMAB-BBDZ) - SANDOZ INC
- Sandoz received a supplemental approval (SUPPL AP) for Jubbonti, a biosimilar of denosumab (active ingredient denosumab-bbdz), used for bone-loss conditions including postmenopausal osteoporosis and bone metastases; denosumab inhibits RANK ligand, a key driver of osteoclast-mediated bone destruction.
TALZENNA (TALAZOPARIB TOSYLATE) - PFIZER
- Pfizer received supplemental approvals on two NDA numbers (NDA217439 and NDA211651) for Talzenna, a PARP inhibitor (talazoparib tosylate) used in BRCA-mutated breast and prostate cancers; PARP inhibitors block DNA repair in cancer cells with pre-existing DNA repair deficiencies.
INGREZZA (VALBENAZINE TOSYLATE) - NEUROCRINE
- Neurocrine Biosciences received a supplemental approval for Ingrezza (valbenazine tosylate, NDA209241), a VMAT2 inhibitor approved for tardive dyskinesia and chorea associated with Huntington's disease, reducing involuntary movements driven by dopamine dysregulation.
AWIQLI FLEXTOUCH (INSULIN ICODEC) - NOVO NORDISK
- Novo Nordisk received a supplemental approval for Awiqli FlexTouch (insulin icodec, BLA761326), a once-weekly basal insulin analog designed to reduce the injection burden for type 2 diabetes patients compared to daily insulin regimens.
MONOFERRIC (FERRIC DERISOMALTOSE) - PHARMACOSMOS
- Pharmacosmos received a supplemental approval for Monoferric (ferric derisomaltose, NDA208171), an intravenous iron replacement therapy indicated for iron deficiency anemia, including in patients who cannot tolerate or absorb oral iron.
VALGANCICLOVIR HYDROCHLORIDE - ALEMBIC
- Alembic Pharmaceuticals received an original approval (ORIG AP) for a generic valganciclovir hydrochloride (ANDA217267), an antiviral prodrug of ganciclovir used to treat cytomegalovirus (CMV) retinitis and prevent CMV disease in transplant recipients.
EPINEPHRINE - GLAND PHARMA
- Gland Pharma received an original approval for a generic epinephrine injection (ANDA220400), the first-line treatment for anaphylaxis and cardiac arrest.
🧪 CLINICAL TRIALS
COMBINED VS. MULTICOMPONENT EXERCISE IN CHRONIC KIDNEY DISEASE (CKD)
- A new randomized controlled trial (NCT07901621, registered 30 October 2026) will compare 12 weeks of combined training (aerobic plus resistance) versus multicomponent training (aerobic plus resistance plus balance) in adults aged 55 to 70 with CKD stages 3a and 3b, versus a non-exercising control group.
- CKD accelerates musculoskeletal aging and cardiovascular risk; the trial aims to determine whether adding balance training to standard combined exercise provides additional functional benefit in this older adult population.
BPL-1357 UNIVERSAL INFLUENZA VACCINE CHALLENGE STUDY
- Trial NCT07215858 is testing BPL-1357, a broad-spectrum influenza vaccine candidate, against an H1N1 influenza virus controlled human infection challenge, addressing the need for pandemic-capable vaccines that go beyond seasonal strain-specific coverage.
- Annual influenza causes 3 to 5 million severe cases and up to 500,000 deaths globally; a broadly protective vaccine would represent a major public health advance.
WARRIOR TRIAL - WOMEN WITH NON-OBSTRUCTIVE CAD
- The WARRIOR trial (NCT03417388), a multicenter prospective randomized study, is evaluating intensive medical treatment versus standard care in women with ischemia and non-obstructive coronary artery disease (INOCA), a condition disproportionately affecting older women and often underdiagnosed.
IMATINIB FOR GERMLINE RUNX1 DEFICIENCY
- Trial NCT06090669 is testing imatinib (a tyrosine kinase inhibitor) to increase RUNX1 transcription factor activity in patients with germline RUNX1 deficiency, a condition causing bleeding disorders and elevated risk of blood cancers; this is a rare disease with limited therapeutic options.
PREOPERATIVE RADIATION FOR RECURRENT ADRENOCORTICAL CARCINOMA
- Trial NCT06487481 is evaluating preoperative external beam radiation therapy in participants with resectable recurrent abdominal adrenocortical carcinoma (ACC), a rare cancer with less than 35% five-year survival; the study is testing whether pre-surgical radiation can improve resectability and outcomes.
177Lu-DOTA-EB-TATE FOR HURTHLE CELL THYROID CANCER
- Trial NCT06991738 is testing a targeted radioligand therapy, 177Lu-DOTA-EB-TATE, in adults with metastatic, radioactive iodine non-responsive oncocytic (Hurthle cell) thyroid cancer, a rare malignancy with few treatment options; the drug targets somatostatin receptors overexpressed on these tumor cells.
📢 PUBLIC HEALTH
LISTERIA FOOD SAFETY ALERT
- CDC urges all U.S. consumers as of 30 October 2026 to inspect home refrigerators and freezers for recalled prepared meal products linked to an ongoing Listeria outbreak; affected items should not be eaten and should be discarded immediately even if they show no signs of spoilage.
SALMONELLA IN MORINGA SUPPLEMENTS - NEW CLUSTER
- 11 people across 7 states have fallen ill as of 31 October 2026 in a Salmonella outbreak tied to moringa leaf, an ingredient found in powdered dietary supplements; consumers should check supplement labels and stop use of any moringa-containing products pending further CDC guidance.
CDC IMMUNIZATION SCHEDULE UPDATE
- CDC updated its adult and child immunization schedules in October 2025 to apply individual-based decision-making for COVID-19 vaccines and introduced standalone chickenpox vaccination for toddlers; the revised schedule reflects a broader shift in CDC policy toward personalized vaccine decisions.
U.S. WHO WITHDRAWAL - BIOSURVEILLANCE CONTEXT
- The United States formally completed withdrawal from WHO on 22 January 2026; WHO expressed regret, noting the decision makes both the U.S. and the world less safe; the withdrawal has practical implications for information-sharing during active outbreaks like the ongoing BVD epidemic.
- CDC's Traveler-Based Genomic Surveillance program surpassed one million voluntary air travel participants as of January 2026, a domestic biosurveillance mechanism that may partially offset reduced multilateral data access.
TICK BITE SURVEILLANCE - USA
- CDC data from April 2026 showed weekly emergency room visits for tick bites were higher than usual for the season, with public health resources available to help individuals protect against tick-borne diseases including Lyme disease and Rocky Mountain spotted fever.
This briefing is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider for personal health decisions.
📎 Sources
- Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus – Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
- CDC Mobilizes International Response Following Ebola Disease O… — CDC Newsroom
Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20261031-02-v122 · 2026-10-31 02:01 UTC · pulse.uzylab.com